Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

1.

Occurrence of Distal Colorectal Neoplasia Among Whites and Blacks Following Negative Flexible Sigmoidoscopy: An Analysis of PLCO Trial.

Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Hickey T, Riley T, Church TR, Weissfeld J, Schoen RE, Marcus PM, Prorok PC.

J Gen Intern Med. 2015 Apr 3. [Epub ahead of print]

PMID:
25835747
2.

Conceptualizing overdiagnosis in cancer screening.

Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS.

J Natl Cancer Inst. 2015 Feb 6;107(4). pii: djv014. doi: 10.1093/jnci/djv014. Print 2015 Apr.

PMID:
25663695
3.

Interval lung cancers not detected on screening chest X-rays: How are they different?

Kvale PA, Johnson CC, Tammem├Ągi M, Marcus PM, Zylak CJ, Spizarny DL, Hocking W, Oken M, Commins J, Ragard L, Hu P, Berg C, Prorok P.

Lung Cancer. 2014 Oct;86(1):41-6. doi: 10.1016/j.lungcan.2014.07.013. Epub 2014 Jul 24.

PMID:
25123333
4.

Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Marcus PM, Ogden SL, Gren LH, Childs JC, Pretzel SM, Lamerato LE, Walsh K, Rozjabek HM, Mabie J, Thomas B, Riley T.

Prev Med. 2014 Oct;67:82-8. doi: 10.1016/j.ypmed.2014.07.013. Epub 2014 Jul 16.

PMID:
25038532
5.

Estimating overdiagnosis in lung cancer screening.

Marcus PM.

JAMA Intern Med. 2014 Jul;174(7):1198. doi: 10.1001/jamainternmed.2014.1546. No abstract available.

PMID:
25003884
6.

Results of the two incidence screenings in the National Lung Screening Trial.

Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gatsonis CA, Gierada DS, Jain A, Jones GC, Mahon I, Marcus PM, Rathmell JM, Sicks J; National Lung Screening Trial Research Team.

N Engl J Med. 2013 Sep 5;369(10):920-31. doi: 10.1056/NEJMoa1208962.

7.

Culturally sensitive approaches to recruitment and retention of Hispanics in the national lung screening trial.

Tenorio SL, O'Donnell CI, Hernandez J, Rozjabek HM, Lynch D, Marcus PM.

J Immigr Minor Health. 2014 Aug;16(4):761-4. doi: 10.1007/s10903-013-9862-0.

PMID:
23780349
8.

Results of initial low-dose computed tomographic screening for lung cancer.

National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S.

N Engl J Med. 2013 May 23;368(21):1980-91. doi: 10.1056/NEJMoa1209120.

9.

Factors associated with the risk of adenoma recurrence in distal and proximal colon.

Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Marcus PM, Schoen RE, Lanza E, Cross AJ.

Digestion. 2013;87(3):141-6. doi: 10.1159/000346281. Epub 2013 Mar 15.

10.

Obesity, weight change, and risk of adenoma recurrence: a prospective trial.

Laiyemo AO, Doubeni C, Badurdeen DS, Murphy G, Marcus PM, Schoen RE, Lanza E, Smoot DT, Cross AJ.

Endoscopy. 2012 Sep;44(9):813-8. doi: 10.1055/s-0032-1309837. Epub 2012 Aug 27.

11.

Recruitment methods employed in the National Lung Screening Trial.

Marcus PM, Lenz S, Sammons D, Black W, Garg K.

J Med Screen. 2012 Jun;19(2):94-102. doi: 10.1258/jms.2012.012016. Epub 2012 May 31.

12.

Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey.

Doria-Rose VP, White MC, Klabunde CN, Nadel MR, Richards TB, McNeel TS, Rodriguez JL, Marcus PM.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1049-59. doi: 10.1158/1055-9965.EPI-12-0343. Epub 2012 May 9.

13.

Tracking and tracing of participants in two large cancer screening trials.

Marcus PM, Childs J, Gahagan B, Gren LH.

Contemp Clin Trials. 2012 Jul;33(4):601-5. doi: 10.1016/j.cct.2012.04.006. Epub 2012 Apr 26.

14.

Equilibrium lines and barriers to phase transitions: the cubic diamond to beta-tin transition in Si from first principles.

Qiu SL, Marcus PM.

J Phys Condens Matter. 2012 Jun 6;24(22):225501. doi: 10.1088/0953-8984/24/22/225501. Epub 2012 May 3.

PMID:
22551557
15.

Lung cancer screening practices of primary care physicians: results from a national survey.

Klabunde CN, Marcus PM, Han PK, Richards TB, Vernon SW, Yuan G, Silvestri GA.

Ann Fam Med. 2012 Mar-Apr;10(2):102-10. doi: 10.1370/afm.1340.

16.

New models for large prospective studies: is there a better way?

Manolio TA, Weis BK, Cowie CC, Hoover RN, Hudson K, Kramer BS, Berg C, Collins R, Ewart W, Gaziano JM, Hirschfeld S, Marcus PM, Masys D, McCarty CA, McLaughlin J, Patel AV, Peakman T, Pedersen NL, Schaefer C, Scott JA, Sprosen T, Walport M, Collins FS.

Am J Epidemiol. 2012 May 1;175(9):859-66. doi: 10.1093/aje/kwr453. Epub 2012 Mar 12.

17.

Screening for Prostate Cancer with Prostate-Specific Antigen: What's the Evidence?

Marcus PM, Kramer BS.

Am Soc Clin Oncol Educ Book. 2012:96-100. doi: 10.14694/EdBook_AM.2012.32.96.

18.

Factors associated with inadequate colorectal cancer screening with flexible sigmoidoscopy.

Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Sanderson AK 2nd, Bresalier R, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD.

Cancer Epidemiol. 2012 Aug;36(4):395-9. doi: 10.1016/j.canep.2011.10.013. Epub 2011 Nov 22.

19.

The National Lung Screening Trial's Endpoint Verification Process: determining the cause of death.

Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD.

Contemp Clin Trials. 2011 Nov;32(6):834-40. doi: 10.1016/j.cct.2011.07.003. Epub 2011 Jul 18. Review.

20.

Reduced lung-cancer mortality with low-dose computed tomographic screening.

National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD.

N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk